What is Zacks Research’s Estimate for PAHC Q1 Earnings?

Phibro Animal Health Co. (NASDAQ:PAHC) – Analysts at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for shares of Phibro Animal Health in a research report issued on Thursday, November 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.31 for the quarter, down from their prior estimate of $0.32. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.61 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q2 2026 earnings at $0.47 EPS, Q4 2026 earnings at $0.49 EPS and FY2026 earnings at $1.60 EPS.

PAHC has been the topic of a number of other research reports. JPMorgan Chase & Co. assumed coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. Barclays upped their target price on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Bank of America lifted their price target on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Finally, StockNews.com upgraded Phibro Animal Health from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 28th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Phibro Animal Health presently has an average rating of “Hold” and an average price target of $16.50.

Phibro Animal Health Stock Performance

Shares of PAHC stock opened at $23.26 on Monday. The firm has a market capitalization of $942.03 million, a price-to-earnings ratio of 54.09, a PEG ratio of 0.61 and a beta of 0.51. The stock has a fifty day moving average of $23.37 and a 200 day moving average of $20.30. Phibro Animal Health has a 52 week low of $9.94 and a 52 week high of $25.98. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Institutional Investors Weigh In On Phibro Animal Health

Several large investors have recently bought and sold shares of the business. Sofinnova Investments Inc. bought a new stake in shares of Phibro Animal Health in the second quarter worth $3,975,000. Acadian Asset Management LLC grew its stake in shares of Phibro Animal Health by 6.3% during the 2nd quarter. Acadian Asset Management LLC now owns 717,506 shares of the company’s stock valued at $12,027,000 after purchasing an additional 42,299 shares during the period. Algert Global LLC increased its position in shares of Phibro Animal Health by 521.1% during the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company’s stock valued at $1,606,000 after purchasing an additional 59,850 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Phibro Animal Health in the third quarter worth approximately $70,000. Finally, Dana Investment Advisors Inc. grew its position in Phibro Animal Health by 17.2% during the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after buying an additional 75,546 shares during the period. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a yield of 2.06%. Phibro Animal Health’s payout ratio is currently 111.63%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.